EU regulators highlight SME/public sector role in new drug approvals
This article was originally published in Scrip
Larger firms may account for the vast majority (87%) of new medicines recommended for approval by the European Medicines Agency, but smaller firms, academia, public bodies and public/private partnerships (PPPs) are responsible for initiating the development of than 40% of these products.
You may also be interested in...
The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.
The TGA has taken a series of actions to address supply chain issues, including on the regulatory front, but it says more remains to be done and is asking stakeholders for suggestions in a new online survey.
As talks restart this week on a future pandemic accord, the international drug industry body, the IFPMA, has reiterated its concerns over the negotiating text, saying some measures could “severely hinder responses to future pandemics.”